Industry: Pharmaceuticals, Biotechnology
Transave, Inc. (the “Company”) is a privately held biopharmaceutical company with the time-cost characteristics of late stage companies. The Company is focused on the development of multiple product lines for the site-specific treatment of lung disease. Transave’s approach is based on its proprietary Sustained-release Lipid Inhaled Targeting (“SLITÔ”) technology. The initial focus is the reformulation off-patent pharmaceuticals transformed into unique SLIT-based inhaled pharmaceuticals for the localized, site specific treatment of lung disease. SLIT technology allows sustained release of the drug in the lung’s microenvironment resulting in enhanced therapeutic benefits and improved dosing ( www.transaveinc.com )
Transave , Inc.
11 Deer Park Drive Suite 117
Monmouth Jct., New Jersey 08852
USA
Tel: (732) 438-9434
Fax: (732) 438-9435